Results 101 to 110 of about 9,852 (179)

P027 | Spalt-like transcription factor 4 deregulation in low risk myelodysplastic syndrome SF3B1-mutated patients

Haematologica
Introduction: Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic stem cell neoplasms characterized by ineffective hematopoiesis, peripheral cytopenias, and variable risk of progression to AML.
Eleonora Lumia
doaj  

Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer. [PDF]

Nat Commun
Wagner V, Bousset L, Ascensão-Ferreira M, Sun B, Barragan Avila JE, Kaizeler A, Martins-Silva R, Rahbari M, Fernández-Vaquero M, Haston S, Tinti M, Pombo J, Khadayate S, Roth S, Schürch CM, Martínez-Barbera JP, Bahat A, Wee KB, Morton JP, Malek N, Innes AJ, Vernia S, Barbosa-Morais NL, Gallage S, Heikenwalder M, Gil J.   +25 more
europepmc   +1 more source

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS). [PDF]

Hemasphere
Maggioni G, Todisco G, Sauta E, Lanino L, Ball S, Bewersdorf JP, Kewan T, Al Ali NH, Fenaux P, Platzbecker U, Santini V, Xie Z, Brunner AM, Kuykendall AT, Bennett JM, Buckstein R, Bejar R, Carraway HE, DeZern AE, Griffiths EA, Halene S, Hasserjian RP, List AF, Loghavi S, Odenike O, Padron E, Patnaik MM, Roboz GJ, Stahl M, Sekeres MA, Steensma DP, Savona MR, Taylor J, Xu ML, Sallman DA, Nimer SD, Hourigan CS, Wei AH, Campagna A, Ubezio M, Riva E, Ventura D, Pinocchio N, Zampini M, Buizza A, Russo A, Pesce F, D'Amico S, Asti G, Delleani M, Travaglino E, Tentori CA, Ferrari I, Crespi A, Figini G, Di Matteo M, Brindisi M, Manes N, Milanesi C, Crisafulli L, Ficara F, Castellani G, Borate UM, Efficace F, Gore SD, Kim TK, Diez-Campelo M, van de Loosdrecht AA, Daver N, Rozman M, Orfao A, Wang SA, Foucar K, Iastrebner M, Scheinberg P, Miyazaki Y, Madanat YF, Al-Kali A, Mittelmann M, Cluzeau T, Ades L, Germing U, Garcia-Manero G, Kordasti S, Haferlach T, Zeidan AM, Komrokji RS, Della Porta MG, An international study on behalf of GenoMed4all, Synthema, and icMDS consortia.   +90 more
europepmc   +1 more source

CO36 | TGF-β pathway deregulation in SF3B1-mutated low risk myelodysplastic syndrome patients

Haematologica
Introduction. Myelodysplastic syndromes (MDS) associated with mutations in genes belonging to the splicing machinery, such as SF3B1, SRSF2, U2AF1 and ZRSR2, are characterized by inefficient hematopoiesis and variable risk of evolving into AML. Mutations
Eleonora Lumia
doaj  

Circulating Tumor DNA Monitoring in Patients with Uveal Melanoma Using Mutation-Agnostic Multiplex Drop-Off ddPCR Assays. [PDF]

Anal Chem
Rampanou A, Rodrigues M, Bidard FC, Cassoux N, Matet A, Vincent-Salomon A, Jeannot E, Bieche I, Roman-Roman S, Stern MH, Renault S.   +10 more
europepmc   +1 more source

Outstanding Questions to Understand and Target Splicing Factor-Mutant Blood Cancers. [PDF]

Blood Cancer Discov
Maron MI, Abdel-Wahab O.
europepmc   +1 more source

SF3B1 mutation arises at the multipotent HSC level [PDF]

Blood, 2017
openaire   +2 more sources

Clinical implications of variant allele frequencies of genes in patients with acute myeloid leukemia. [PDF]

Oncologist
Zhao L, Cheng F, Wei J, Liu R, Zhao Q, Zhang Y, Li Y.   +6 more
europepmc   +1 more source

Clinical Characteristics and Molecular Profiling of <i>SF3B1</i>-Mutated Myelodysplastic Syndrome (MDS) in a Real-World Practice. [PDF]

Int J Mol Sci
Wang RR, Than H, Tham C, How GF, Khoo SJ, Tuy TT.   +5 more
europepmc   +1 more source

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML? [PDF]

Blood Neoplasia
Komrokji RS, Komrokji Z, Al Ali NH, Xie Z, Chan O, Kuykendall AT, Walker AR, Yun S, Reynolds SB, Shallis R, Lancet JE, Sallman DA, Padron E.   +12 more
europepmc   +1 more source